Method of implanting an adjustable occlusion device

Information

  • Patent Grant
  • 9943299
  • Patent Number
    9,943,299
  • Date Filed
    Friday, January 24, 2014
    10 years ago
  • Date Issued
    Tuesday, April 17, 2018
    6 years ago
Abstract
Disclosed is an adjustable occlusion device for use in a body lumen such as the left atrial appendage. The occlusion device is removably carried by a deployment catheter. The device may be enlarged or reduced to facilitate optimal placement or removal. Methods are also disclosed.
Description
BACKGROUND OF THE INVENTION

Embolic stroke is the nation's third leading killer for adults, and is a major cause of disability. There are over 700,000 strokes per year in the United States alone. Of these, roughly 100,000 are hemorrhagic, and 600,000 are ischemic (either due to vessel narrowing or to embolism). The most common cause of embolic stroke emanating from the heart is thrombus formation due to atrial fibrillation. Approximately 80,000 strokes per year are attributable to atrial fibrillation. Atrial fibrillation is an arrhythmia of the heart that results in a rapid and chaotic heartbeat that produces lower cardiac output and irregular and turbulent blood flow in the vascular system. There are over five million people worldwide with atrial fibrillation, with about four hundred thousand new cases reported each year. Atrial fibrillation is associated with a 500 percent greater risk of stroke due to the condition. A patient with atrial fibrillation typically has a significantly decreased quality of life due, in part, to the fear of a stroke, and the pharmaceutical regimen necessary to reduce that risk.


For patients who develop atrial thrombus from atrial fibrillation, the clot normally occurs in the left atrial appendage (LAA) of the heart. The LAA is a cavity which looks like a small finger or windsock and which is connected to the lateral wall of the left atrium between the mitral valve and the root of the left pulmonary vein. The LAA normally contracts with the rest of the left atrium during a normal heart cycle, thus keeping blood from becoming stagnant therein, but often fails to contract with any vigor in patients experiencing atrial fibrillation due to the discoordinate electrical signals associated with AF. As a result, thrombus formation is predisposed to form in the stagnant blood within the LAA.


Blackshear and Odell have reported that of the 1288 patients with non-rheumatic atrial fibrillation involved in their study, 221 (17%) had thrombus detected in the left atrium of the heart. Blackshear J L, Odell J A., Appendage Obliteration to Reduce Stroke in Cardiac Surgical Patients With Atrial Fibrillation. Ann Thorac. Surg., 1996.61(2):755-9. Of the patients with atrial thrombus, 201 (91%) had the atrial thrombus located within the left atrial appendage. The foregoing suggests that the elimination or containment of thrombus formed within the LAA of patients with atrial fibrillation would significantly reduce the incidence of stroke in those patients.


Pharmacological therapies for stroke prevention such as oral or systemic administration of warfarin or the like have been inadequate due to serious side effects of the medications and lack of patient compliance in taking the medication. Invasive surgical or thorascopic techniques have been used to obliterate the LAA, however, many patients are not suitable candidates for such surgical procedures due to a compromised condition or having previously undergone cardiac surgery. In addition, the perceived risks of even a thorascopic surgical procedure often outweigh the potential benefits. See Blackshear and Odell, above. See also Lindsay B D., Obliteration of the Left Atrial Appendage: A Concept Worth Testing, Ann Thorac. Surg., 1996.61(2):515.


Despite the various efforts in the prior art, there remains a need for a minimally invasive method and associated devices for reducing the risk of thrombus formation in the left atrial appendage.


SUMMARY OF THE INVENTION

There is provided in accordance with one aspect of the present invention an adjustable occlusion device deployment system, for implanting an occlusion device within a tubular structure in the body. The system comprises an occlusion device, movable between a reduced cross section and an enlarged cross section. A deployment catheter is provided, releasably attached to the occlusion device. A releasable lock for retaining the occlusion device is provided on the catheter, along with a core, for changing the cross section of the occlusion device.


The occlusion device comprises an expandable frame, which may have at least two and preferably at least about six spokes. In one embodiment, the occlusion device has sixteen spokes. Each spoke is moveable from an axial orientation when the occlusion device is in a reduced cross section, to an inclined orientation when the occlusion device is in an enlarged cross section. Preferably, at least one tissue attachment element is provided on the occlusion device.


In accordance with another aspect of the present invention, there is provided an occlusion device for occluding a tubular body structure. The device comprises a plurality of spokes, which are moveable between an axial orientation and an inclined orientation. A threaded aperture is carried by the device, and a stop surface is also carried by the device. A threaded core is rotatable within the aperture, to cause the core to contact the stop surface and axially elongate the device.


In accordance with a further aspect of the present invention, there is provided an implantable device. The device comprises a radially enlargeable frame having a proximal end and a distal end. A proximally facing stop surface is provided within the frame, and a threaded aperture is positioned in the frame, proximally of the stop surface. Distal axial advancement of a threaded core through the threaded aperture distally advances the stop surface, thereby axially elongating and radially reducing the implantable device. In one embodiment, the implantable device is an occlusion device. In an alternate embodiment, the implantable device is a filter.


In accordance with another aspect of the present invention, there is provided an occlusion device implantation system. The system comprises a deployment catheter, having an elongate flexible body with a proximal end and a distal end. An anti-rotation lock is provided on the body. A rotatable core extends axially through the body, and a radially expandable implant is releasably connected to the distal end of the body.


In accordance with a further aspect of the present invention, there is provided a method of implanting a device in the left atrial appendage. The method comprises the steps of providing a deployment catheter, having an elongate flexible body with a proximal end and a distal end, a control on the proximal end and a device removably carried by the distal end. At least a portion of the device is positioned within the left atrial appendage, and the control is manipulated to enlarge the device under positive force.


In one application of the invention, the manipulating step comprises rotating the control. In general, the device comprises an expandable frame having at least two and preferably at least about six spokes. Each spoke is movable from an axial orientation when the device is in a reduced cross section to an inclined orientation when the device is in an enlarged cross section.


In accordance with a further aspect of the present invention, there is provided a method of removing a device having tissue anchors thereon, from a site in the body. The method comprises the steps of positioning a retrieval catheter with respect to the device such that the anchors are within a flared distal end on the retrieval catheter. The diameter of the flared distal end is reduced, with the anchors therein. The retrieval catheter is thereafter removed from the site. In one aspect of the method, the reducing step comprises positioning the flared distal end within an outer tubular sleeve.


In accordance with a further aspect of the present invention, there is provided a retrieval catheter for retrieving a device from an implantation site within the body. The retrieval catheter comprises an elongate flexible body, having a proximal end and a distal end. A grasping structure is provided on or carried within the flexible body, for grasping the device, and a flared tubular sleeve is provided for surrounding at least a portion of the device. An outer tubular sleeve, for surrounding the flared tubular sleeve is also provided. The flared tubular sleeve in one embodiment comprises a plurality of petals, which are movable between an axial orientation and an inclined orientation.


Further features and advantages of the present invention will become apparent to those of ordinary skill in the art in view of the detailed description of preferred embodiments which follows, when considered together with the attached drawings and claims.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a perspective view of an occlusion device in accordance with the present invention.



FIG. 2 is a side elevational view of the occlusion device shown in FIG. 1.



FIG. 3 is a perspective view of an alternate embodiment of the present invention.



FIG. 4 is a side elevational view of the embodiment shown in FIG. 3.



FIG. 5 is a perspective view of a further embodiment of the present invention.



FIG. 6 is a side elevational view of the embodiment of FIG. 5.



FIG. 7 is a perspective view of a support structure for a further occlusion device in accordance with the present invention.



FIG. 7A is a side elevational view of the device of FIG. 7.



FIG. 7B is an end view taken along the line 7B-7B of FIG. 7A.



FIG. 8 is a schematic illustration of an inflatable balloon positioned within the occlusion device of FIG. 7.



FIG. 9 is a schematic view of a pull string deployment embodiment of the occlusion device of FIG. 7.



FIGS. 10 and 11 are side elevational schematic representations of partial and complete barrier layers on the occlusion device of FIG. 7.



FIG. 12 is a side elevational schematic view of an alternate occlusion device in accordance with the present invention.



FIG. 13 is a schematic view of a bonding layer mesh for use in forming a composite barrier membrane in accordance with the present invention.



FIG. 14 is an exploded cross sectional view of the components of a composite barrier member in accordance with the present invention.



FIG. 15 is a cross sectional view through a composite barrier formed from the components illustrated in FIG. 14.



FIG. 16 is a top plan view of the composite barrier illustrated in FIG. 15.



FIG. 17 is a schematic view of a deployment system in accordance with the present invention.



FIG. 17A is an enlarged view of a releasable lock in an engaged configuration.



FIG. 17B is an enlarged view as in FIG. 17A, with the core axially retracted to release the implant.



FIG. 18 is a perspective view of a flexible guide tube for use in the configurations of FIG. 17 and/or FIG. 19.



FIG. 19 is a schematic view of an alternate deployment system in accordance with the present invention.



FIGS. 19A and 19B illustrate a removal sequence for an implanted device in accordance with the present invention.



FIG. 20 is a schematic cross sectional view through the distal end of a retrieval catheter having an occlusion device removably connected thereto.



FIG. 20A is a side elevational schematic view of the system illustrated in FIG. 20, with the occlusion device axially elongated and radially reduced.



FIG. 20B is a side elevational schematic view as in FIG. 20A, with the occlusion device drawn part way into the delivery catheter.



FIG. 20C is a schematic view as in FIG. 20B, with the occlusion device and delivery catheter drawn into a transeptal sheath.





DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENT

Referring to FIGS. 1 and 2, there is illustrated one embodiment of the occlusion device 10 in accordance with the present invention. Although the present invention will be described primarily in the context of an occlusion device, the present inventors also contemplate omitting the fabric cover or enlarging the pore size to produce implantable filters or other devices which are enlargeable at a remote implantation site.


The occlusion device 10 comprises an occluding member 11 comprising a frame 14 and a barrier 15. In the illustrated embodiment, the frame 14 comprises a plurality of radially outwardly extending spokes 17 each having a length within the range of from about 0.5 cm to about 2 cm from a hub 16. In one embodiment, the spokes have an axial length of about 1.5 cm. Depending upon the desired introduction crossing profile of the collapsed occlusion device 10, as well as structural strength requirements in the deployed device, anywhere within the range of from about 3 spokes to about 40 spokes may be utilized. In some embodiments, anywhere from about 12 to about 24 spokes are utilized, and, 18 spokes are utilized in one embodiment.


The spokes are advanceable from a generally axially extending orientation such as to fit within a tubular introduction catheter to a radially inclined orientation as illustrated in FIG. 1 and FIG. 2 following deployment from the catheter. In a self-expandable embodiment, the spokes are biased radially outwardly such that the occlusion member expands to its enlarged, implantation cross-section under its own bias following deployment from the catheter. Alternatively, the occlusion member may be enlarged using any of a variety of enlargement structures such as an inflatable balloon, or a catheter for axially shortening the occlusion member, as is discussed further below.


Preferably, the spokes comprise a metal such as stainless steel, Nitinol, Elgiloy, or others which can be determined through routine experimentation by those of skill in the art. Wires having a circular or rectangular cross-section may be utilized depending upon the manufacturing technique. In one embodiment, rectangular cross section spokes are cut such as by known laser cutting techniques from tube stock, a portion of which forms the hub 16.


The barrier 15 may comprise any of a variety of materials which facilitate cellular in-growth, such as ePTFE. The suitability of alternate materials for barrier 15 can be determined through routine experimentation by those of skill in the art. The barrier 15 may be provided on either one or both axially facing sides of the occlusion member. In one embodiment, the barrier 15 comprises two layers, with one layer on each side of the frame 14. The two layers may be bonded to each other around the spokes 17 in any of a variety of ways, such as by heat bonding with or without an intermediate bonding layer such as polyethylene or FEP, adhesives, sutures, and other techniques which will be apparent to those of skill in the art in view of the disclosure herein. The barrier 15 preferably has a thickness of no more than about 0.003″ and a porosity within the range of from about 5 .mu.m to about 60 .mu.m.


The barrier 15 in one embodiment preferably is securely attached to the frame 14 and retains a sufficient porosity to facilitate cellular ingrowth and/or attachment. One method of manufacturing a suitable composite membrane barrier 15 is illustrated in FIGS. 13-16. As illustrated schematically in FIG. 13, a bonding layer 254 preferably comprises a mesh or other porous structure having an open surface area within the range of from about 10% to about 90%. Preferably, the open surface area of the mesh is within the range of from about 30% to about 60%. The opening or pore size of the bonding layer 254 is preferably within the range of from about 0.005 inches to about 0.050 inches, and, in one embodiment, is about 0.020 inches. The thickness of the bonding layer 254 can be varied widely, and is generally within the range of from about 0.0005 inches to about 0.005 inches. In a preferred embodiment, the bonding layer 254 has a thickness of about 0.001 to about 0.002 inches. One suitable polyethylene bonding mesh is available from Smith and Nephew, under the code SN9.


Referring to FIG. 14, the bonding layer 254 is preferably placed adjacent one or both sides of a spoke or other frame element 14. The bonding layer 254 and frame 14 layers are then positioned in-between a first membrane 250 and a second membrane 252 to provide a composite membrane stack. The first membrane 250 and second membrane 252 may comprise any of a variety of materials and thicknesses, depending upon the desired functional result. Generally, the membrane has a thickness within the range of from about 0.0005 inches to about 0.010 inches. In one embodiment, the membranes 250 and 252 each have a thickness on the order of from about 0.001 inches to about 0.002 inches, and comprise porous ePTFE, having a porosity within the range of from about 10 microns to about 100 microns.


The composite stack is heated to a temperature of from about 200.degree. to about 300.degree., for about 1 minute to about 5 minutes under pressure to provide a finished composite membrane assembly with an embedded frame 14 as illustrated schematically in FIG. 15. The final composite membrane has a thickness within the range of from about 0.001 inches to about 0.010 inches, and, preferably, is about 0.002 to about 0.003 inches in thickness. However, the thicknesses and process parameters of the foregoing may be varied considerably, depending upon the materials of the bonding layer 254 the first layer 250 and the second layer 252.


As illustrated in top plan view in FIG. 16, the resulting finished composite membrane has a plurality of “unbonded” windows or areas 256 suitable for cellular attachment and/or ingrowth. The attachment areas 256 are bounded by the frame 14 struts, and the cross-hatch or other wall pattern formed by the bonding layer 254. Preferably, a regular window 256 pattern is produced in the bonding layer 254.


The foregoing procedure allows the bonding mesh to flow into the first and second membranes 250 and 252 and gives the composite membrane 15 greater strength (both tensile and tear strength) than the components without the bonding mesh. The composite allows uniform bonding while maintaining porosity of the membrane 15, to facilitate tissue attachment. By flowing the thermoplastic bonding layer into the pores of the outer mesh layers 250 and 252, the composite flexibility is preserved and the overall composite layer thickness can be minimized.


Referring back to FIGS. 1 and 2, the occlusion device 10 may be further provided with a bulking element or stabilizer 194. The stabilizer 194 may be spaced apart along an axis from the occluding member 11. In the illustrated embodiment, a distal end 190 and a proximal end 192 are identified for reference. The designation proximal or distal is not intended to indicate any particular anatomical orientation or deployment orientation within the deployment catheter. As shown in FIGS. 1 and 2, the stabilizer 194 is spaced distally apart from the occluding member 11.


For use in the LAA, the occluding member 11 has an expanded diameter within the range of from about 1 cm to about 5 cm, and, in one embodiment, about 3 cm. The axial length of the occluding member 11 in an expanded, unstressed orientation from the distal end 192 to the hub 16 is on the order of about 1 cm. The overall length of the occlusion device 10 from the distal end 192 to the proximal end 190 is within the range of from about 1.5 cm to about 4 cm and, in one embodiment, about 2.5 cm. The axial length of the stabilizer 194 between distal hub 191 and proximal hub 16 is within the range of from about 0.5 cm to about 2 cm, and, in one embodiment, about 1 cm. The expanded diameter of the stabilizer 194 is within the range of from about 0.5 cm to about 2.5 cm, and, in one embodiment, about 1.4 cm. The outside diameter of the distal hub 191 and proximal hub 16 is about 2.5 mm.


Preferably, the occlusion device 10 is provided with one or more retention structures for retaining the device in the left atrial appendage or other body cavity or lumen. In the illustrated embodiment, a plurality of barbs or other anchors 195 are provided, for engaging adjacent tissue to retain the occlusion device 10 in its implanted position and to limit relative movement between the tissue and the occlusion device. The illustrated anchors are provided on one or more of the spokes 17, or other portion of frame 14. Preferably, every spoke, every second spoke or every third spoke are provided with one or two or more anchors each.


The illustrated anchor is in the form of a barb, with one on each spoke for extending into tissue at or near the opening of the LAA. Depending upon the embodiment, two or three barbs may alternatively be desired on each spoke. In the single barb embodiment of FIG. 7, each barb is inclined in a proximal direction. This is to inhibit proximal migration of the implant out of the left atrial appendage. In this context, distal refers to the direction into the left atrial appendage, and proximal refers to the direction from the left atrial appendage into the heart.


Alternatively, one or more barbs may face distally, to inhibit distal migration of the occlusion device deeper into the LAA. Thus the implant may be provided with at least one proximally facing barb and at least one distally facing barb. For example, in an embodiment of the type illustrated in FIG. 12, discussed below, a proximal plurality of barbs may be inclined in a first direction, and a distal plurality of barbs may be inclined in a second direction, to anchor the implant against both proximal and distal migration.


One or more anchors 195 may also be provided on the stabilizer 194, such that it assists not only in orienting the occlusion device 10 and resisting compression of the LAA, but also in retaining the occlusion device 10 within the LAA. Any of a wide variety of structures may be utilized for anchor 195, either on the occluding member 11 or the stabilizer 194 or both, such as hooks, barbs, pins, sutures, adhesives, ingrowth surfaces and others which will be apparent to those of skill in the art in view of the disclosure herein.


In use, the occlusion device 10 is preferably positioned within a tubular anatomical structure to be occluded such as the left atrial appendage. In a left atrial appendage application, the occluding member 11 is positioned across or near the opening to the LAA and the stabilizer 194 is positioned within the LAA. The stabilizer 194 assists in the proper location and orientation of the occluding member 11, as well as resists compression of the LAA behind the occluding member 11. The present inventors have determined that following deployment of an occluding member 11 without a stabilizer 194 or other bulking structure to resist compression of the LAA, normal operation of the heart may cause compression and resulting volume changes in the LAA, thereby forcing fluid past the occluding member 11 and inhibiting or preventing a complete seal. Provision of a stabilizer 194 dimensioned to prevent the collapse or pumping of the LAA thus minimizes leakage, and provision of the barbs facilitates endothelialization or other cell growth across the occluding member 11.


The stabilizer 194 is preferably movable between a reduced cross-sectional profile for transluminal advancement into the left atrial appendage, and an enlarged cross-sectional orientation as illustrated to fill or to substantially fill a cross-section through the LAA. The stabilizing member may enlarge to a greater cross section than the (pre-stretched) anatomical cavity, to ensure a tight fit and minimize the likelihood of compression. One convenient construction includes a plurality of elements 196 which are radially outwardly expandable in response to axial compression of a distal hub 191 towards a proximal hub 16. Elements 196 each comprise a distal segment 198 and a proximal segment 202 connected by a bend 200. The elements 196 may be provided with a bias in the direction of the radially enlarged orientation as illustrated in FIG. 2, or may be radially expanded by applying an expansion force such as an axially compressive force between distal hub 191 and proximal hub 16 or a radial expansion force such as might be applied by an inflatable balloon. Elements 196 may conveniently be formed by laser cutting the same tube stock as utilized to construct the distal hub 191, proximal hub 16 and frame 14, as will be apparent to those of skill in the art in view of the disclosure herein. Alternatively, the various components of the occlusion device 10 may be separately fabricated or fabricated in subassemblies and secured together during manufacturing.


As a post implantation step for any of the occlusion devices disclosed herein, a radiopaque dye or other visualizable media may be introduced on one side or the other of the occlusion device, to permit visualization of any escaped blood or other fluid past the occlusion device. For example, in the context of a left atrial appendage application, the occlusion device may be provided with a central lumen or other capillary tube or aperture which permits introduction of a visualizable dye from the deployment catheter through the occlusion device and into the entrapped space on the distal side of the occlusion device. Alternatively, dye may be introduced into the entrapped space distal to the occlusion device such as by advancing a small gauge needle from the deployment catheter through the barrier 15 on the occlusion device, to introduce dye.


Modifications to the occlusion device 10 are illustrated in FIGS. 3-4. The occlusion device 10 comprises an occlusion member 11 and a stabilizing member 194 as previously discussed. In the present embodiment, however, each of the distal segments 198 inclines radially outwardly in the proximal direction and terminates in a proximal end 204. The proximal end 204 may be provided with an atraumatic configuration, for pressing against, but not penetrating, the wall of the left atrial appendage or other tubular body structure. Three or more distal segments 198 are preferably provided, and generally anywhere within the range of from about 6 to about 20 distal segments 198 may be used. In one embodiment, 9 distal segments 198 are provided. In this embodiment, three of the distal segments 198 have an axial length of about 5 mm, and 6 of the distal segments 198 have an axial length of about 1 cm. Staggering the lengths of the distal segments 198 may axially elongate the zone in the left atrial appendage against which the proximal ends 204 provide anchoring support for the occlusion device.


The occlusion device 10 illustrated in FIGS. 3 and 4 is additionally provided with a hinge 206 to allow the longitudinal axis of the occlusion member 11 to be angularly oriented with respect to the longitudinal axis of the stabilizing member 194. In the illustrated embodiment, the hinge 206 is a helical coil, although any of a variety of hinge structures can be utilized. The illustrated embodiment may be conveniently formed by laser cutting a helical slot through a section of the tube from which the principal structural components of the occlusion device 10 are formed. At the distal end of the hinge 206, an annular band 208 connects the hinge 206 to a plurality of axially extending struts 210. In the illustrated embodiment, three axial struts 210 are provided, spaced equilaterally around the circumference of the body. Axial struts 210 may be formed from a portion of the wall of the original tube stock, which portion is left in its original axial orientation following formation of the distal segments 198 such as by laser cutting from the tubular wall.


The occlusion member 11 is provided with a proximal zone 212 on each of the spokes 17. Proximal zone 212 has an enhanced degree of flexibility, to accommodate the fit between the occlusion member 11 and the wall of the left atrial appendage. Proximal section 212 may be formed by reducing the cross sectional area of each of the spokes 17, which may be provided with a wave pattern as illustrated.


Each of the spokes 17 terminates in a proximal point 214. Proximal point 214 may be contained within layers of the barrier 15, or may extend through or beyond the barrier 15 such as to engage adjacent tissue and assist in retaining the occlusion device 10 at the deployment site.


Referring to FIGS. 5 and 6, a further variation on the occlusion device 10 illustrated in FIGS. 1 and 2 is provided. The occlusion device 10 is provided with a proximal face 216 on the occlusion member 11, instead of the open and proximally concave face on the embodiment of FIGS. 1 and 2. The proximal face 216 is formed by providing a proximal spoke 218 which connects at an apex 220 to some or all of the distal spokes 17. The proximal spoke 218, and corresponding apex 220 and distal spoke 17 may be an integral structure, such as a single ribbon or wire, or element cut from a tube stock as has been discussed.


Proximal spokes 218 are each attached to a hub 222 at the proximal end 192 of the occlusion device 10. The barrier 15 may surround either the proximal face or the distal face or both on the occlusion member 11. In general, provision of a proximal spoke 218 connected by an apex 220 to a distal spoke 17 provides a greater radial force than a distal spoke 17 alone, which will provide an increased resistance to compression if the occlusion member 11 is positioned with the LAA.


Referring to FIGS. 7-12, alternate structures of the occlusion device in accordance with the present invention are illustrated. In general, the occlusion device 10 comprises an occluding member but does not include a distinct stabilizing member as has been illustrated in connection with previous embodiments. Any of the embodiments previously disclosed herein may also be constructed using the occluding member only, and omitting the stabilizing member as will be apparent to those of skill in the art in view of the disclosure herein.


The occluding device 10 comprises a proximal end 192, a distal end 190, and a longitudinal axis extending therebetween. A plurality of supports 228 extend between a proximal hub 222 and a distal hub 191. At least two or three supports 228 are provided, and preferably at least about ten. In one embodiment, sixteen supports 228 are provided. However, the precise number of supports 228 can be modified, depending upon the desired physical properties of the occlusion device 10 as will be apparent to those of skill in the art in view of the disclosure herein, without departing from the present invention.


Each support 228 comprises a proximal spoke portion 218, a distal spoke portion 17, and an apex 220 as has been discussed. Each of the proximal spoke portion 218, distal spoke portion 17 and apex 220 may be a region on an integral support 228, such as a continuous rib or frame member which extends in a generally curved configuration as illustrated with a concavity facing towards the longitudinal axis of the occlusion device 10. Thus, no distinct point or hinge at apex 220 is necessarily provided.


At least some of the supports 228, and, preferably, each support 228, is provided with one or two or more barbs 195. In the illustrated configuration, the occlusion device 10 is in its enlarged orientation, such as for occluding a left atrial appendage or other body cavity or lumen. In this orientation, each of the barbs 195 projects generally radially outwardly from the longitudinal axis, and is inclined in the proximal direction. One or more barbs may also be inclined distally, as is discussed elsewhere herein. In an embodiment where the barbs 195 and corresponding support 228 are cut from a single ribbon, sheet or tube stock, the barb 195 will incline radially outwardly at approximately a tangent to the curve formed by the support 228.


The occlusion device 10 constructed from the frame illustrated in FIG. 7 may be constructed in any of a variety of ways, as will become apparent to those of skill in the art in view of the disclosure herein. In one method, the occlusion device 10 is constructed by laser cutting a piece of tube stock to provide a plurality of axially extending slots in-between adjacent supports 228. Similarly, each barb 195 can be laser cut from the corresponding support 228 or space in-between adjacent supports 228. The generally axially extending slots which separate adjacent supports 228 end a sufficient distance from each of the proximal end 192 and distal end 190 to leave a proximal hub 222 and a distal hub 191 to which each of the supports 228 will attach. In this manner, an integral cage structure may be formed. Alternatively, each of the components of the cage structure may be separately formed and attached together such as through soldering, brazing, heat bonding, adhesives, and other fastening techniques which are known in the art. A further method of manufacturing the occlusion device 10 is to laser cut a slot pattern on a flat sheet of appropriate material, such as a flexible metal or polymer, as has been discussed in connection with previous embodiments. The flat sheet may thereafter be rolled about an axis and opposing edges bonded together to form a tubular structure.


The apex portion 220 which carries the barb 195 may be advanced from a low profile orientation in which each of the supports 228 extend generally parallel to the longitudinal axis, to an implanted orientation as illustrated, in which the apex 220 and the barb 195 are positioned radially outwardly from the longitudinal axis. The support 228 may be biased towards the enlarged orientation, or may be advanced to the enlarged orientation under positive force following positioning within the tubular anatomical structure, in any of a variety of manners.


For an example of enlarging under positive force, referring to FIG. 8, an inflatable balloon 230 is positioned within the occlusion device 10. Inflatable balloon 230 is connected by way of a removable coupling 232 to an inflation catheter 234. Inflation catheter 234 is provided with an inflation lumen for providing communication between an inflation media source 236 outside of the patient and the balloon 230. Following positioning within the target body lumen, the balloon 230 is inflated, thereby engaging barbs 195 with the surrounding tissue. The inflation catheter 234 is thereafter removed, by decoupling the removable coupling 232, and the inflation catheter 234 is thereafter removed. The balloon 230 may be either left in place within the occlusion device 10, or deflated and removed by the inflation catheter 234.


In an alternate embodiment, the supports 228 are radially enlarged such as through the use of a deployment catheter 238. See FIG. 9. Deployment catheter 238 comprises a lumen for movably receiving a deployment element such as a flexible line 240. Deployment line 240 extends in a loop 244 formed by an aperture or slip knot 242. As will be apparent from FIG. 9, proximal refraction on the deployment line 240 while resisting proximal movement of proximal hub 222 such as by using the distal end of the catheter 238 will cause the distal hub 191 to be drawn towards the proximal hub 222, thereby radially enlarging the cross-sectional area of the occlusion device 10. Depending upon the material utilized for the occlusion device 10, the supports 228 will retain the radially enlarged orientation by elastic deformation, or may be retained in the enlarged orientation such as by securing the slip knot 242 immovably to the deployment line 240 at the fully radially enlarged orientation. This may be accomplished in any of a variety of ways, using additional knots, clips, adhesives, or other techniques known in the art.


A variety of alternative structures may be utilized, to open or enlarge the occlusion device 10 under positive force. For example, Referring to FIG. 9, a pullwire 240 may be removably attached to the distal hub 191 or other distal point of attachment on the occlusion device 10. Proximal retraction of the pullwire 240 while resisting proximal motion of the proximal hub 222 such as by using the distal end of the catheter 238 will cause enlargement of the occlusion device 10 as has been discussed. The pullwire 240 may then be locked with respect to the proximal hub 222 and severed or otherwise detached to enable removal of the deployment catheter 238 and proximal extension of the pullwire 240. Locking of the pullwire with respect to the proximal hub 222 may be accomplished in any of a variety of ways, such as by using interference fit or friction fit structures, adhesives, a knot or other technique depending upon the desired catheter design.


Referring to FIGS. 10 and 11, the occlusion device 10 may be provided with a barrier 15 such as a mesh or fabric as has been previously discussed. Barrier 15 may be provided on only one hemisphere such as proximal face 216, or may be carried by the entire occlusion device 10 from proximal end 192 to distal end 190. The barrier may be secured to the radially inwardly facing surface of the supports 228, as illustrated in FIG. 11, or may be provided on the radially outwardly facing surfaces of supports 228, or both.


A further embodiment of the occlusion device 10 is illustrated in FIG. 12, in which the apex 220 is elongated in an axial direction to provide additional contact area between the occlusion device 10 and the wall of the tubular structure. In this embodiment, one or two or three or more anchors 195 may be provided on each support 228, depending upon the desired clinical performance. The occlusion device 10 illustrated in FIG. 12 may also be provided with any of a variety of other features discussed herein, such as a partial or complete barrier 15. In addition, the occlusion device 10 illustrated in FIG. 12 may be enlarged using any of the techniques disclosed elsewhere herein.


Referring to FIG. 17, there is schematically illustrated a further aspect of the present invention. An adjustable implant deployment system 300 comprises generally a catheter 302 for placing a detachable implant 304 within a body cavity or lumen, as has been discussed. The catheter 302 comprises an elongate flexible tubular body 306, extending between a proximal end 308 and a distal end 310. The catheter is shown in highly schematic form, for the purpose of illustrating the functional aspects thereof. The catheter body will have a sufficient length and diameter to permit percutaneous entry into the vascular system, and transluminal advancement through the vascular system to the desired deployment site. For example, in an embodiment intended for access at the femoral artery and deployment within the left atrial appendage, the catheter 302 will have a length within the range of from about 50 cm to about 150 cm, and a diameter of generally no more than about 15 French. Further dimensions and physical characteristics of catheters for navigation to particular sites within the body are well understood in the art and will not be further described herein.


The tubular body 306 is further provided with a handle 309 generally on the proximal end 308 of the catheter 302. The handle 309 permits manipulation of the various aspects of the implant deployment system 300, as will be discussed below. Handle 309 may be manufactured in any of a variety of ways, typically by injection molding or otherwise forming a handpiece for single-hand operation, using materials and construction techniques well known in the medical device arts.


The implant 304 may be in the form of any of those described previously herein, as modified below. In general, the implant is movable from a reduced crossing profile to an enlarged crossing profile, such that it may be positioned within a body structure and advanced from its reduced to its enlarged crossing profile to obstruct bloodflow or perform other functions while anchored therein. The implant 304 may be biased in the direction of the enlarged crossing profile, may be neutrally biased or may be biased in the direction of the reduced crossing profile. Any modifications to the device and deployment system to accommodate these various aspects of the implant 304 may be readily accomplished by those of skill in the art in view of the disclosure herein.


In the illustrated embodiment, the distal end 314 of the implant 304 is provided with an implant plug 316. Implant plug 316 provides a stopping surface 317 for contacting an axially movable core 312. The core 312 extends axially throughout the length of the catheter body 302, and is attached at its proximal end to a core control 332 on the handle 309.


The core 312 may comprise any of a variety of structures which has sufficient lateral flexibility to permit navigation of the vascular system, and sufficient axial column strength to enable reduction of the implant 304 to its reduced crossing profile. Any of a variety of structures such as hypotube, solid core wire, “bottomed out” coil spring structures, or combinations thereof may be used, depending upon the desired performance of the finished device. In one embodiment, the core 312 comprises stainless steel tubing.


The distal end of core 312 is positioned within a recess or lumen 322 defined by a proximally extending guide tube 320. In the illustrated embodiment, the guide tube 320 is a section of tubing such as metal hypotube, which is attached at the distal end 314 of the implant and extends proximally within the implant 304. The guide tube 320 preferably extends a sufficient distance in the proximal direction to inhibit buckling or prolapse of the core 312 when distal pressure is applied to the core control 332 to reduce the profile of the implant 304. However, the guide tube 320 should not extend proximally a sufficient distance to interfere with the opening of the implant 304.


As will be appreciated by reference to FIG. 17, the guide tube 320 may operate as a limit on distal axial advancement of the proximal end 324 of implant 304. Thus, the guide tube 320 preferably does not extend sufficiently far proximally from the distal end 314 to interfere with optimal opening of the implant 304. The specific dimensions are therefore relative, and will be optimized to suit a particular intended application. In one embodiment, the implant 304 has an implanted outside diameter within the range of from about 5 mm to about 45 mm, and an axial implanted length within the range of from about 5 mm to about 45 mm. The guide tube 320 has an overall length of about 3 mm to about 35 mm, and an outside diameter of about 0.095 inches.


An alternate guide tube 320 is schematically illustrated in FIG. 18. In this configuration, the guide tube 320 comprises a plurality of tubular segments 321 spaced apart by an intervening space 323. This allows increased flexibility of the guide tube 320, which may be desirable during the implantation step, while retaining the ability of the guide tube 320 to maintain linearity of the core 312 while under axial pressure. Although three segments 321 are illustrated in FIG. 18, as many as 10 or 20 or more segments 321 may be desirable depending upon the desired flexibility of the resulting implant.


Each adjacent pair of segments 321 may be joined by a hinge element 325 which permits lateral flexibility. In the illustrated embodiment, the hinge element 325 comprises an axially extending strip or spine, which provides column strength along a first side of the guide tube 320. The guide tube 320 may therefore be curved by compressing a second side of the guide tube 320 which is generally offset from the spine 325 by about 180.degree. A limit on the amount of curvature may be set by adjusting the axial length of the space 323 between adjacent segments 321. In an embodiment having axial spines 325, each axial spine 325 may be rotationally offset from the next adjacent axial spine 325 to enable flexibility of the overall guide tube 320 throughout a 360.degree. angular range of motion.


Alternatively, the flexible hinge point between each adjacent segment 321 may be provided by cutting a spiral groove or plurality of parallel grooves in a tubular element in between what will then become each adjacent pair of segments 321. In this manner, each tubular element 321 will be separated by an integral spring like structure, which can permit flexibility. As a further alternative, the entire length of the guide tube 320 may comprise a spring. Each of the forgoing embodiments may be readily constructed by laser cutting or other cutting from a piece of tube stock, to produce a one piece guide tube 320. Alternatively, the guide tube 320 may be assembled from separate components and fabricated together using any of a variety of bonding techniques which are appropriate for the construction material selected for the tube 320.


Various distal end 314 constructions may be utilized, as will be apparent to those of skill in the art in view of the disclosure herein. In the illustrated embodiment, the distal implant plug 316 extends within the implant 304 and is attached to the distal end of the guide tube 320. The implant plug 316 may be secured to the guide tube 320 and implant 304 in any of a variety of ways, depending upon the various construction materials. For example, any of a variety of metal bonding techniques such as a welding, brazing, interference fit such as threaded fit or snap fit, may be utilized. Alternatively, any of a variety of bonding techniques for dissimilar materials may be utilized, such as adhesives, and various molding techniques. In one construction, the implant plug 316 comprises a molded polyethylene cap, and is held in place utilizing a distal cross pin 318 which extends through the implant 304, the guide tube 320 and the implant plug 316 to provide a secure fit against axial displacement.


The proximal end 324 of the implant 304 is provided with a releasable lock 326 for attachment to a release element such as pull wire 328. Pull wire 328 extends proximally throughout the length of the tubular body 306 to a proximal pull wire control 330 on the handle 309.


As used herein, the term pull wire is intended to include any of a wide variety of structures which are capable of transmitting axial tension or compression such as a pushing or pulling force with or without rotation from the proximal end 308 to the distal end 310 of the catheter 302. Thus, monofilament or multifilament metal or polymeric rods or wires, woven or braided structures may be utilized. Alternatively, tubular elements such as a concentric tube positioned within the outer tubular body 306 may also be used as will be apparent to those of skill in the art.


In the illustrated embodiment, the pull wire 328 is releasably connected to the proximal end 324 of the implant 304. This permits proximal advancement of the proximal end of the implant 304, which cooperates with a distal retention force provided by the core 312 against the distal end of the implant to axially elongate the implant 304 thereby reducing it from its implanted configuration to its reduced profile for implantation. The proximal end of the pull wire 328 may be connected to any of a variety of pull wire controls 330, including rotational knobs, levers and slider switches, depending upon the design preference.


The proximal end 324 of the implant 304 is thus preferably provided with a releasable lock 326 for attachment of the pullwire 328 to the deployment catheter. In the illustrated embodiment, the releasable lock is formed by advancing the pullwire distally around a cross pin 329, and providing an eye or loop which extends around the core 312. As long as the core 312 is in position within the implant 304, proximal retraction of the pullwire 328 will advance the proximal end 324 of the implant 304 in a proximal direction. See FIG. 17A. However, following deployment, proximal retraction of the core 312 such as by manipulation of the core control 332 will pull the distal end of the core 312 through the loop on the distal end of the pullwire 328. The pullwire 328 may then be freely proximally removed from the implant 304, thereby enabling detachment of the implant 304 from the deployment system 300 within a treatment site. See FIG. 17B.


The implant deployment system 300 thus permits the implant 304 to be maintained in a low crossing profile configuration, to enable transluminal navigation to a deployment site. Following positioning at or about the desired deployment site, proximal retraction of the core 312 enables the implant 304 to radially enlarge under its own bias to fit the surrounding tissue structure. Alternatively, the implant can be enlarged under positive force, such as by inflation of a balloon or by a mechanical mechanism as is discussed elsewhere herein. Once the clinician is satisfied with the position of the implant 304, such as by injection of dye and visualization using conventional techniques, the core 312 is proximally retracted thereby releasing the lock 326 and enabling detachment of the implant 304 from the deployment system 300.


If, however, visualization reveals that the implant 304 is not at the location desired by the clinician, proximal retraction of the pull wire 328 with respect to the core 312 will radially reduce the diameter of the implant 304, thereby enabling repositioning of the implant 304 at the desired site. Thus, the present invention permits the implant 304 to be enlarged or reduced by the clinician to permit repositioning and/or removal of the implant 304 as may be desired.


In an alternate construction, the implant may be radially enlarged or reduced by rotating a torque element extending throughout the deployment catheter. Referring to FIG. 19, the elongate flexible tubular body 306 of the deployment catheter 302 includes a rotatable torque rod 340 extending axially therethrough. The proximal end of the torque rod 340 may be connected at a proximal manifold to a manual rotation device such as a hand crank, thumb wheel, rotatable knob or the like. Alternatively, the torque rod 340 may be connected to a power driven source of rotational energy such as a motor drive or air turbine.


The distal end of the torque rod 340 is integral with or is connected to a rotatable core 342 which extends axially through the implant 304. A distal end 344 of the rotatable core 342 is positioned within a cavity 322 as has been discussed.


The terms torque rod or torque element are intended to include any of a wide variety of structures which are capable of transmitting a rotational torque throughout the length of a catheter body. For example, solid core elements such as stainless steel, nitinol or other nickel titanium alloys, or polymeric materials may be utilized. In an embodiment intended for implantation over a guide-wire, the torque rod 340 is preferably provided with an axially extending central guidewire lumen. This may be accomplished by constructing the torque rod 340 from a section of hypodermic needle tubing, having an inside diameter of from about 0.001 inches to about 0.005 inches or more greater than the outside diameter of the intended guidewire. Tubular torque rods 340 may also be fabricated or constructed utilizing any of a wide variety of polymeric constructions which include woven or braided reinforcing layers in the wall. Torque transmitting tubes and their methods of construction are well understood in the intracranial access and rotational atherectomy catheter arts, among others, and are not described in greater detail herein. Use of a tubular torque rod 340 also provides a convenient infusion lumen for injection of contrast media within the implant 304, such as through a port 343.


The proximal end 324 of the implant 304 is provided with a threaded aperture 346 through which the core 342 is threadably engaged. As will be appreciated by those of skill in the art in view of the disclosure herein, rotation of the threaded core 342 in a first direction relative to the proximal end 324 of the implant 304 will cause the rotatable core 342 to advance distally. This distal advancement will result in an axial elongation and radial reduction of the implantable device 304. Rotation of the rotatable core 342 in a reverse direction will cause a proximal retraction of the rotatable core 342, thus enabling a radial enlargement and axial shortening of the implantable device 304.


The deployment catheter 302 is further provided with an antirotation lock 348 between a distal end 350 of the tubular body 306 and the proximal end 324 of the implant 304. In general, the rotational lock 348 may be conveniently provided by cooperation between a first surface 352 on the distal end 350 of the deployment catheter 302, which engages a second surface 354 on the proximal end 324 of the implantable device 304, to rotationally link the deployment catheter 302 and the implantable device 304. Any of a variety of complementary surface structures may be provided, such as an axial extension on one of the first and second surfaces for coupling with a corresponding recess on the other of the first and second surfaces. Such extensions and recesses may be positioned laterally offset from the axis of the catheter. Alternatively, they may be provided on the longitudinal axis with any of a variety of axially releasable anti-rotational couplings having at least one flat such as a hexagonal or other multifaceted cross sectional configuration.


As schematically illustrated in FIG. 19, one or more projections 356 on the first surface 352 may engage a corresponding recess 358 on the second surface 354. Any of a variety of alternative complementary surface structures may also be provided, as will be apparent to those of skill in the art in view of the disclosure herein. For example, referring to FIG. 19A, the projection 356 is in the form of an axially extending pin for engaging a complimentary recess 358 on the proximal end 324 of the implant 304. FIG. 19B illustrates an axially extending spline 356 for receipt within a complimentary axially extending recess 358. The various pin, spline and other structures may be reversed between the distal end of tubular body 306 and the proximal end 324 of the implant 304 as will be apparent to those of skill in the art in view of the disclosure herein.


Upon placement of the implantable device 304 at the desired implantation site, the torque rod 340 is rotated in a direction that produces an axial proximal retraction. This allows radial enlargement of the radially outwardly biased implantable device 304 at the implantation site. Continued rotation of the torque rod 340 will cause the threaded core 342 to exit proximally through the threaded aperture 346. At that point, the deployment catheter 302 may be proximally refracted from the patient, leaving the implanted device 304 in place.


By modification of the decoupling mechanism to allow the core 342 to be decoupled from the torque rod 340, the rotatable core 342 may be left within the implantable device 304, as may be desired depending upon the intended deployment mechanism. For example, the distal end of the core 342 may be rotatably locked within the end cap 326, such as by including complimentary radially outwardly or inwardly extending flanges and grooves on the distal end of the core 342 and inside surface of the cavity 322. In this manner, proximal retraction of the core 342 by rotation thereof relative to the implantable device 304 will pull the end cap 326 in a proximal direction under positive force. This may be desirable as a supplement to or instead of a radially enlarging bias built into the implantable device 304.


In the embodiment illustrated in FIG. 19, or any other of the deployment and/or removal catheters described herein, the distal end of the tubular body 306 may be provided with a zone or point of enhanced lateral flexibility. This may be desirable in order allow the implant to seat in the optimal orientation within the left atrial appendage, and not be restrained by a lack of flexibility in the tubular body 306. This may be accomplished in any of a variety of way, such as providing the distal most one or two or three centimeters or more of the tubular body 306 with a spring coil configuration. In this manner, the distal end of the tubular body 306 will be sufficiently flexible to allow the implant 304 to properly seat within the LAA. This distal flex zone on the tubular body 306 may be provided in any of a variety of ways, such as by cutting a spiral slot in the distal end of the tubular body 306 using laser cutting or other cutting techniques. The components within the tubular body 306 such as torque rod 340 may similarly be provided with a zone of enhanced flexibility in the distal region of the tubular body 306.


The implantable device 304 may also be retrieved and removed from the body in accordance with a further aspect of the present invention. One manner of retrieval and removal will be understood in connection with FIGS. 20 through 20c. Referring to FIG. 20, a previously implanted device 304 is illustrated as releasably coupled to the distal end of the tubular body 306, as has been previously discussed. Coupling may be accomplished by aligning the tubular body 306 with the proximal end 324 of the deployed implant 304, under fluoroscopic visualization, and distally advancing a rotatable core 342 through the threaded aperture 346. Threadable engagement between the rotatable core 342 and aperture 346 may thereafter be achieved, and distal advancement of core 342 will axially elongate and radially reduce the implant 304.


The tubular body 306 is axially moveably positioned within an outer tubular delivery or retrieval catheter 360. Catheter 360 extends from a proximal end (not illustrated) to a distal end 362. The distal end 362 is preferably provided with a flared opening, such as by constructing a plurality of petals 364 for facilitating proximal retraction of the implant 304 as will become apparent. Petals 364 may be constructed in a variety of ways, such as by providing axially extending slits in the distal end 362 of the delivery catheter 360. In this manner, preferably at least about three, and generally at least about four or five or six petals or more will be provided on the distal end 362 of the delivery catheter 360. Petals 364 manufactured in this manner would reside in a first plane, transverse to the longitudinal axis of the delivery catheter 360, if each of such petals 364 were inclined at 90 degrees to the longitudinal axis of the delivery catheter 360.


In one application of the invention, a second layer of petals 365 are provided, which would lie in a second, adjacent plane if the petals 365 were inclined at 90 degrees to the longitudinal axis of the delivery catheter 360. Preferably, the second plane of petals 365 is rotationally offset from the first plane of petals 364, such that the second petals 365 cover the spaces 367 formed between each adjacent pair of petals 365. The use of two or more layers of staggered petals 364 and 365 has been found to be useful in retrieving implants 304, particularly when the implant 304 carries a plurality of tissue anchors 195.


The petals 364 and 365 may be manufactured from any of a variety of polymer materials useful in constructing medical device components such as the delivery catheter 360. This includes, for example, polyethylene, PET, PEEK, PEBAX, and others well known in the art. The second petals 365 may be constructed in any of a variety of ways. In one convenient construction, a section of tubing which concentrically fits over the delivery catheter 360 is provided with a plurality of axially extending slots in the same manner as discussed above. The tubing with a slotted distal end may be concentrically positioned on the catheter 360, and rotated such that the space between adjacent petals 365 is offset from the space between adjacent petals 364. The hub of the petals 365 may thereafter be bonded to the catheter 360, such as by heat shrinking, adhesives, or other bonding techniques known in the art.


The removal sequence will be further understood by reference to FIGS. 20a through 20c. Referring to FIG. 20a, the radially reduced implant 304 is proximally retracted part way into the delivery catheter 360. This can be accomplished by proximally retracting the tubular body 306 and/or distally advancing the catheter 360. As illustrated in FIG. 20b, the tubular body 306 having the implant 304 attached thereto is proximally retracted a sufficient distance to position the tissue anchors 195 within the petals 364. The entire assembly of the tubular body 306, within the delivery catheter 360 may then be proximally retracted within the transeptal sheath 366 or other tubular body as illustrated in FIG. 20c. The collapsed petals 364 allow this to occur while preventing engagement of the tissue anchors 195 with the distal end of the transeptal sheath 366 or body tissue. The entire assembly having the implantable device 304 contained therein may thereafter be proximally withdrawn from or repositioned within the patient.


While particular forms of the invention have been described, it will be apparent that various modifications can be made without departing from the spirit and scope of the invention. Accordingly, it is not intended that the invention be limited, except as by the appended claims.

Claims
  • 1. An implantable left atrial appendage occlusion device comprising: an occluding member, enlargeable from a reduced cross-section configuration to an enlarged cross-section configuration; anda stabilizing member,wherein the stabilizing member is enlargeable from a reduced cross-section state to an enlarged cross-section state,wherein a cross-sectional area of the enlarged cross-section state of the stabilizing member is less than a cross-sectional area of the enlarged cross-section configuration of the occluding member,wherein the stabilizing member comprises at least three radially outwardly moveable segments inclined radially outward in a proximal direction to terminate at atraumatic free ends, andwherein the occluding member includes a membrane or mesh.
  • 2. The implantable left atrial appendage occlusion device of claim 1, further comprising a hub between the occluding member and the stabilizing member.
  • 3. The implantable left atrial appendage occlusion device of claim 2, wherein the occluding member comprises an expandable frame.
  • 4. The implantable left atrial appendage occlusion device of claim 3, wherein the frame comprises at least two spokes.
  • 5. The implantable left atrial appendage occlusion device of claim 4, wherein at least one spoke of the at least two spokes has a first end and a second end, and the first end is attached to the hub.
  • 6. The implantable left atrial appendage occlusion device of claim 1, wherein the stabilizing member comprises at least two segments which are movable from an axial orientation when the stabilizing member is in the reduced cross-section state to an inclined orientation when the stabilizing member is in the enlarged cross-section state.
  • 7. The implantable left atrial appendage occlusion device of claim 6, wherein each segment of the at least two segments of the stabilizing member comprises a proximal section, a distal section, and a bend in between the proximal section and the distal section when the stabilizing member is in the enlarged cross-section state.
  • 8. The implantable left atrial appendage occlusion device of claim 6, wherein each element of the at least two segments of the stabilizing member comprises wire.
  • 9. The implantable left atrial appendage occlusion device of claim 6, wherein the at least two segments of the stabilizing member are integrally formed.
  • 10. The implantable left atrial appendage occlusion device of claim 1, further comprising at least one tissue attachment element on the occluding member or on the stabilizing member or on both.
  • 11. The implantable left atrial appendage occlusion device of claim 10, wherein the at least one tissue attachment structure comprises a tissue piercing element.
  • 12. An implantable left atrial appendage occlusion device comprising: a body having a longitudinal axis;an expandable occluding member at a first position on the longitudinal axis; anda stabilizing member at a second position on the longitudinal axis,wherein the stabilizing member comprises at least three radially outwardly moveable segments inclined radially outward in a proximal direction to terminate at atraumatic free ends,wherein the expandable occluding member comprises a plurality of spokes which are hingedly attached to the body and movable between an axial orientation and a radially outwardly inclined orientation.
  • 13. The implantable left atrial appendage occlusion device of claim 12, further comprising a membrane or mesh carried by the plurality of spokes.
  • 14. The implantable left atrial appendage occlusion device of claim 12, wherein the at least three radially outwardly moveable segments comprise flexible metal.
  • 15. The implantable left atrial appendage occlusion device of claim 12, further comprising a hinge on the body between the expandable occluding member and the stabilizing member.
  • 16. The implantable left atrial appendage occlusion device of claim 15, wherein the hinge comprises a coil.
  • 17. The implantable left atrial appendage occlusion device of claim 12, wherein at least one spoke of the plurality of spokes of the expandable occluding member is configured and adapted to engage tissue and to assist in retaining the implantable left atrial appendage occlusion device at a deployment site.
RELATED APPLICATIONS

This application is a continuation of U.S. application Ser. No. 13/274,380, filed Oct. 17, 2011, now U.S. Pat. No. 8,663,273, which is a continuation of U.S. application Ser. No. 11/434,012, filed May 15, 2006, now U.S. Pat. No. 8,043,329, which is a continuation of U.S. application Ser. No. 10/033,371, filed Oct. 19, 2001, now U.S. Pat. No. 7,044,134, which is a continuation-in-part of U.S. application Ser. No. 09/435,562, filed Nov. 8, 1999, now U.S. Pat. No. 7,128,073, the complete disclosure of which are incorporated by reference herein.

US Referenced Citations (347)
Number Name Date Kind
178283 French Jun 1876 A
1967318 Monahan Jul 1934 A
3402710 Maurice Sep 1968 A
3540431 Mobin Nov 1970 A
3557794 Van Patten Jan 1971 A
3638652 Kelley Feb 1972 A
3811449 Gravlee et al. May 1974 A
3844302 Klein Oct 1974 A
3874388 King Apr 1975 A
4007743 Blake Feb 1977 A
4175545 Termanini Nov 1979 A
4309776 Berguer Jan 1982 A
4341218 U et al. Jul 1982 A
4425908 Simon Jan 1984 A
4585000 Hershenson et al. Apr 1986 A
4603693 Conta et al. Aug 1986 A
4611594 Grayhack et al. Sep 1986 A
4619246 Molgaard-Nielsen Oct 1986 A
4638803 Rand et al. Jan 1987 A
4665906 Jervis et al. May 1987 A
4681588 Ketharanathan et al. Jul 1987 A
4710192 Liotta et al. Dec 1987 A
4718417 Kittrell et al. Jan 1988 A
4759348 Cawood et al. Jul 1988 A
4781177 Lebigot Nov 1988 A
4793348 Palmaz Dec 1988 A
4827907 Tashiro May 1989 A
4832055 Palestrant May 1989 A
4917089 Sideris Apr 1990 A
4921484 Hillstead May 1990 A
4960412 Fink Oct 1990 A
4966150 Etienne et al. Oct 1990 A
4998972 Chin et al. Mar 1991 A
5037810 Saliba, Jr. Aug 1991 A
5041090 Scheglov et al. Aug 1991 A
5041093 Chu Aug 1991 A
5042707 Taheri et al. Aug 1991 A
5053009 Herzerg et al. Oct 1991 A
5064435 Porter Nov 1991 A
5071407 Termin et al. Dec 1991 A
5078736 Behl Jan 1992 A
5098440 Hillstead Mar 1992 A
5108418 Lefebvre Apr 1992 A
5108420 Marks Apr 1992 A
5108474 Riedy et al. Apr 1992 A
5116360 Pinchuk et al. May 1992 A
5122136 Guglielmi et al. Jun 1992 A
5171259 Inoue Dec 1992 A
5176692 Wilk et al. Jan 1993 A
5192301 Kamiya Mar 1993 A
5211658 Clouse May 1993 A
5234458 Metals Aug 1993 A
5256146 Ensminger et al. Oct 1993 A
5258000 Gianturco Nov 1993 A
5258042 Mehta Nov 1993 A
5284488 Sideris et al. Feb 1994 A
5304184 Hathaway et al. Apr 1994 A
5306234 Johnson Apr 1994 A
5312341 Turi May 1994 A
5334217 Das et al. Aug 1994 A
5344439 Otten Sep 1994 A
5350398 Pavcnik et al. Sep 1994 A
5350399 Erlebacher et al. Sep 1994 A
5353784 Nady Oct 1994 A
5370657 Irie Dec 1994 A
5375612 Cottenceau Dec 1994 A
5397331 Himpens et al. Mar 1995 A
5397355 Marin et al. Mar 1995 A
5417699 Klein et al. May 1995 A
5421832 Lefebvre Jun 1995 A
5425744 Fagan et al. Jun 1995 A
5427119 Swartz et al. Jun 1995 A
5433727 Sideris Jul 1995 A
5443454 Tanabe et al. Aug 1995 A
5443478 Purdy et al. Aug 1995 A
5451235 Lock Sep 1995 A
5454365 Bonutti Oct 1995 A
5464408 Duc Nov 1995 A
5469867 Schmitt et al. Nov 1995 A
5490856 Person et al. Feb 1996 A
5497774 Swartz et al. Mar 1996 A
5499975 Cope et al. Mar 1996 A
5499995 Teirstein Mar 1996 A
5522790 Moll et al. Jun 1996 A
5522822 Phelps et al. Jun 1996 A
5522836 Palermo Jun 1996 A
5527322 Klein et al. Jun 1996 A
5527338 Purdy Jun 1996 A
5558093 Pomeranz et al. Sep 1996 A
5558652 Henke Sep 1996 A
5569204 Cramer et al. Oct 1996 A
5591196 Marin et al. Jan 1997 A
5614204 Cochrum Mar 1997 A
5634936 Linden et al. Jun 1997 A
5634942 Chevillon et al. Jun 1997 A
5637097 Yoon et al. Jun 1997 A
5643282 Kieturakis et al. Jul 1997 A
5643292 Hart Jul 1997 A
5649953 Lefebvre Jul 1997 A
5653690 Booth et al. Aug 1997 A
5662671 Barbut et al. Sep 1997 A
5669933 Simon Sep 1997 A
5681345 Euteneuer Oct 1997 A
5683411 Kavteladze Nov 1997 A
5693067 Purdy et al. Dec 1997 A
5695525 Mulhauser et al. Dec 1997 A
5700285 Myers et al. Dec 1997 A
5702421 Schneidt Dec 1997 A
5704910 Humes Jan 1998 A
5709224 Behl et al. Jan 1998 A
5709704 Nott et al. Jan 1998 A
5709707 Lock Jan 1998 A
5722400 Ockuly et al. Mar 1998 A
5724975 Negus et al. Mar 1998 A
5725512 Swartz et al. Mar 1998 A
5725552 Kotula et al. Mar 1998 A
5725568 Hastings Mar 1998 A
5733294 Forber et al. Mar 1998 A
5733302 Myler et al. Mar 1998 A
5735290 Sterman et al. Apr 1998 A
5749880 Banas et al. May 1998 A
5749883 Halpern May 1998 A
5749894 Engelson et al. May 1998 A
5766219 Horton et al. Jun 1998 A
5769816 Barbut et al. Jun 1998 A
5776097 Massoud Jul 1998 A
5782860 Epstein et al. Jul 1998 A
5785679 Abolfathi et al. Jul 1998 A
5800454 Jacobsen et al. Sep 1998 A
5800457 Gelbfish Sep 1998 A
5800512 Letnz et al. Sep 1998 A
5807261 Benaron et al. Sep 1998 A
5810874 Lefebvre Sep 1998 A
5814028 Swartz et al. Sep 1998 A
5814029 Hassett et al. Sep 1998 A
5820591 Thompson et al. Oct 1998 A
5823198 Jones et al. Oct 1998 A
5830228 Knapp et al. Nov 1998 A
5833673 Ockuly et al. Nov 1998 A
5836913 Orth et al. Nov 1998 A
5836968 Simon et al. Nov 1998 A
5840027 Swartz et al. Nov 1998 A
5843118 Sepetka et al. Dec 1998 A
5846260 Maahs Dec 1998 A
5846261 Kotula et al. Dec 1998 A
5848969 Panescu et al. Dec 1998 A
5849005 Garrison et al. Dec 1998 A
5851232 Lois Dec 1998 A
5853422 Huebsch et al. Dec 1998 A
5855597 Jayarman Jan 1999 A
5865791 Whayne et al. Feb 1999 A
5865802 Yoon et al. Feb 1999 A
5868708 Hart et al. Feb 1999 A
5876367 Kaganov et al. Mar 1999 A
5879296 Ockuly et al. Mar 1999 A
5879366 Shaw et al. Mar 1999 A
5882340 Yoon et al. Mar 1999 A
5885258 Sachdeva et al. Mar 1999 A
5891558 Bell et al. Apr 1999 A
5895399 Barbut et al. Apr 1999 A
5904680 Kordis et al. May 1999 A
5904703 Gilson May 1999 A
5906207 Shen May 1999 A
5910154 Tsugita et al. Jun 1999 A
5911734 Tsugita et al. Jun 1999 A
5916236 Muijs Van De Moer et al. Jun 1999 A
5925063 Khosravi Jul 1999 A
5925074 Gingras et al. Jul 1999 A
5925075 Myers et al. Jul 1999 A
5928192 Maahs Jul 1999 A
5928260 Chin et al. Jul 1999 A
5935145 Villar et al. Aug 1999 A
5935147 Kensey et al. Aug 1999 A
5935148 Villar et al. Aug 1999 A
5941249 Maynard Aug 1999 A
5941896 Kerr Aug 1999 A
5944738 Amplatz Aug 1999 A
5947997 Pavcnik et al. Sep 1999 A
5951589 Epstein et al. Sep 1999 A
5951599 McCrory Sep 1999 A
5954694 Sunseri Sep 1999 A
5957940 Tanner et al. Sep 1999 A
5961545 Lentz et al. Oct 1999 A
5976174 Ruiz Nov 1999 A
5980555 Barbut et al. Nov 1999 A
5989281 Barbut et al. Nov 1999 A
5993469 McKenzie et al. Nov 1999 A
5993483 Gianotti Nov 1999 A
5997557 Barbut et al. Dec 1999 A
6004280 Buck et al. Dec 1999 A
6004348 Banas et al. Dec 1999 A
6007523 Mangosong et al. Dec 1999 A
6007557 Ambrisco et al. Dec 1999 A
6010517 Baccaro et al. Jan 2000 A
6010522 Barbut et al. Jan 2000 A
6013093 Nott et al. Jan 2000 A
6024751 Lovato et al. Feb 2000 A
6024754 Engelson et al. Feb 2000 A
6024755 Addis et al. Feb 2000 A
6024756 Huebsch et al. Feb 2000 A
6027520 Tsugita et al. Feb 2000 A
6033420 Hahnen Mar 2000 A
6036720 Abrams et al. Mar 2000 A
6042598 Tsugita et al. Mar 2000 A
6048331 Tsugita et al. Apr 2000 A
6051014 Jang Apr 2000 A
6051015 Maahs Apr 2000 A
6056720 Morse May 2000 A
6063070 Eder May 2000 A
6063113 Kavteladze May 2000 A
6066126 Li et al. May 2000 A
6068621 Balceta et al. May 2000 A
6074357 Kaganov et al. Jun 2000 A
6076012 Swanson et al. Jun 2000 A
6079414 Roth Jun 2000 A
6080182 Shaw et al. Jun 2000 A
6080183 Tsugita et al. Jun 2000 A
6083239 Addis Jul 2000 A
6090084 Hassell et al. Jul 2000 A
6096052 Callister et al. Aug 2000 A
6096053 Bates et al. Aug 2000 A
6110243 Wnenchak et al. Aug 2000 A
6123715 Amplatz Sep 2000 A
6124523 Banas et al. Sep 2000 A
6132438 Fleischman et al. Oct 2000 A
6136016 Barbut et al. Oct 2000 A
6139527 Laufer et al. Oct 2000 A
6139573 Sogard et al. Oct 2000 A
6152144 Lesh Nov 2000 A
6156055 Ravenscroft Dec 2000 A
6161543 Cox et al. Dec 2000 A
6171329 Shaw et al. Jan 2001 B1
6179859 Bates et al. Jan 2001 B1
6203531 Ockuly et al. Mar 2001 B1
6206907 Marino Mar 2001 B1
6214029 Thill et al. Apr 2001 B1
6221092 Koike Apr 2001 B1
6231561 Frazier et al. May 2001 B1
6231589 Wessman May 2001 B1
6245012 Kleshinski Jun 2001 B1
6251122 Tsukernik Jun 2001 B1
6258115 Dubrul Jul 2001 B1
6267776 O'Connell Jul 2001 B1
6270530 Eldridge et al. Aug 2001 B1
6270902 Tedeschi et al. Aug 2001 B1
6277138 Levinson et al. Aug 2001 B1
6285898 Ben-Haim Sep 2001 B1
6290674 Roue et al. Sep 2001 B1
6290708 Kugel et al. Sep 2001 B1
6312407 Zadno-Azizi et al. Nov 2001 B1
6328727 Frazier et al. Dec 2001 B1
6342062 Suon et al. Jan 2002 B1
6346116 Brooks et al. Feb 2002 B1
6361545 Macoviak et al. Mar 2002 B1
6364895 Greenhalgh Apr 2002 B1
6368338 Konya Apr 2002 B1
6371971 Tsugita et al. Apr 2002 B1
6375670 Greenhalgh Apr 2002 B1
6391044 Yadav et al. May 2002 B1
6398803 Layne et al. Jun 2002 B1
6402746 Whayne et al. Jun 2002 B1
6402779 Colone et al. Jun 2002 B1
6419669 Frazier et al. Jul 2002 B1
6440152 Gainor et al. Aug 2002 B1
6443972 Bosma et al. Sep 2002 B1
6447530 Ostrovsky Sep 2002 B1
6468291 Bates et al. Oct 2002 B2
6468301 Amplatz et al. Oct 2002 B1
6488689 Kaplan et al. Dec 2002 B1
6511496 Huter et al. Jan 2003 B1
6514280 Gilson Feb 2003 B1
6517573 Pollock et al. Feb 2003 B1
6547815 Myers Apr 2003 B2
6551303 Van Tassel Apr 2003 B1
6551344 Thill Apr 2003 B2
6558401 Azizi May 2003 B1
6558405 McInnes May 2003 B1
6558414 Layne May 2003 B2
6562058 Seguin et al. May 2003 B2
6589251 Yee et al. Jul 2003 B2
6599308 Amplatz Jul 2003 B2
6623508 Shaw et al. Sep 2003 B2
6650923 Lesh et al. Nov 2003 B1
6652555 VanTassel et al. Nov 2003 B1
6652556 VanTassel et al. Nov 2003 B1
6666861 Grabek Dec 2003 B1
6689150 VanTassel et al. Feb 2004 B1
6699260 Dubrul et al. Mar 2004 B2
6699276 Sogard et al. Mar 2004 B2
6702825 Frazier et al. Mar 2004 B2
6726701 Gilson et al. Apr 2004 B2
6730108 Van Tassel et al. May 2004 B2
6827737 Hill et al. Dec 2004 B2
6837901 Rabkin et al. Jan 2005 B2
6855153 Saadat Feb 2005 B2
6911037 Gainor et al. Jun 2005 B2
6932838 Schwartz et al. Aug 2005 B2
6949113 Van Tassel et al. Sep 2005 B2
6994092 van der Burg et al. Feb 2006 B2
7011671 Welch Mar 2006 B2
7014645 Greene, Jr. et al. Mar 2006 B2
7044134 Khairkhahan et al. May 2006 B2
7128073 van der Burg et al. Oct 2006 B1
7152605 Khairkhahan et al. Dec 2006 B2
7169164 Borillo et al. Jan 2007 B2
7713282 Frazier et al. May 2010 B2
7722641 van der Burg et al. May 2010 B2
7799049 Ostrovsky et al. Sep 2010 B2
8043329 Khairkhahan et al. Oct 2011 B2
8080032 van der Burg et al. Dec 2011 B2
8287563 Khairkhahan et al. Oct 2012 B2
8323309 Khairkhahan et al. Dec 2012 B2
8523897 Van Der Burg et al. Sep 2013 B2
8535343 Van Der Burg et al. Sep 2013 B2
8663273 Khairkhahan et al. Mar 2014 B2
8685055 VanTassel et al. Apr 2014 B2
20010020181 Layne Sep 2001 A1
20010034537 Shaw et al. Oct 2001 A1
20010037141 Yee et al. Nov 2001 A1
20020022860 Borillo et al. Feb 2002 A1
20020035374 Borillo et al. Mar 2002 A1
20020045931 Sogard et al. Apr 2002 A1
20020062133 Gilson et al. May 2002 A1
20020082675 Myers Jun 2002 A1
20020099439 Schwartz et al. Jul 2002 A1
20020111647 Khairkhahan et al. Aug 2002 A1
20020138094 Borillo et al. Sep 2002 A1
20020138097 Ostrovsky et al. Sep 2002 A1
20020169475 Gainor et al. Nov 2002 A1
20020177855 Greene, Jr. et al. Nov 2002 A1
20030023262 Welch Jan 2003 A1
20030023266 Borillo et al. Jan 2003 A1
20030057156 Peterson et al. Mar 2003 A1
20030060871 Hill et al. Mar 2003 A1
20030120337 Van Tassel et al. Jun 2003 A1
20030181942 Sutton et al. Sep 2003 A1
20030191526 Van Tassel et al. Oct 2003 A1
20030195555 Khairkhahan et al. Oct 2003 A1
20030204203 Khairkhahan et al. Oct 2003 A1
20030220667 van der Burg et al. Nov 2003 A1
20040034366 van der Burg et al. Feb 2004 A1
20040049210 Vantassel et al. Mar 2004 A1
20040098031 van der Burg et al. May 2004 A1
20040122467 VanTassel et al. Jun 2004 A1
20040220610 Kreidler et al. Nov 2004 A1
20040230222 van der Burg et al. Nov 2004 A1
20050203568 Burg et al. Sep 2005 A1
Foreign Referenced Citations (32)
Number Date Country
9313712 Jul 1993 WO
9504132 Feb 1995 WO
9522359 Aug 1995 WO
9601591 Jan 1996 WO
9640356 Dec 1996 WO
9728749 Aug 1997 WO
9735522 Oct 1997 WO
9802100 Jan 1998 WO
9817187 Apr 1998 WO
9823322 Jun 1998 WO
9827868 Jul 1998 WO
9905977 Feb 1999 WO
9907289 Feb 1999 WO
9908607 Feb 1999 WO
9923976 May 1999 WO
9925252 May 1999 WO
9930640 Jun 1999 WO
9944510 Sep 1999 WO
0016705 Mar 2000 WO
0027292 May 2000 WO
0067669 Nov 2000 WO
0108743 Feb 2001 WO
0115629 Mar 2001 WO
0130266 May 2001 WO
0130267 May 2001 WO
0130268 May 2001 WO
0215793 Feb 2002 WO
0224106 Mar 2002 WO
02071977 Sep 2002 WO
03007825 Jan 2003 WO
03008030 Jan 2003 WO
03032818 Apr 2003 WO
Non-Patent Literature Citations (4)
Entry
PCT Search Report from co-pending Application PCT/US02/33808 dated May 20, 2003.
Written Opinion for co-pending PCT/US/02/33808 dated Nov. 17, 2003.
International Search Report and Written Opinion from PCT/US2004/008109 dated Aug. 3, 2004.
PCT Search Report for co-pending Application PCT/US99/26325 dated Feb. 15, 2000.
Related Publications (1)
Number Date Country
20140148842 A1 May 2014 US
Continuations (3)
Number Date Country
Parent 13274380 Oct 2011 US
Child 14163578 US
Parent 11434012 May 2006 US
Child 13274380 US
Parent 10033371 Oct 2001 US
Child 11434012 US
Continuation in Parts (1)
Number Date Country
Parent 09435562 Nov 1999 US
Child 10033371 US